Drug Interactions between famotidine and Odactra
This report displays the potential drug interactions for the following 2 drugs:
- famotidine
- Odactra (house dust mite allergen extract)
Interactions between your drugs
No interactions were found between famotidine and Odactra. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
famotidine
A total of 314 drugs are known to interact with famotidine.
- Famotidine is in the drug class H2 antagonists.
-
Famotidine is used to treat the following conditions:
- Allergic Urticaria (off-label)
- Cutaneous Mastocytosis
- Duodenal Ulcer
- Duodenal Ulcer Prophylaxis
- Erosive Esophagitis
- GERD
- Hiatal Hernia (off-label)
- Indigestion
- Laryngopharyngeal Reflux (off-label)
- Pathological Hypersecretory Conditions
- Peptic Ulcer
- Stomach Ulcer
- Upper GI Hemorrhage
- Urticaria (off-label)
- Zollinger-Ellison Syndrome
Odactra
A total of 139 drugs are known to interact with Odactra.
- Odactra is in the drug class allergenics.
- Odactra is used to treat Allergic Rhinitis.
Drug and food interactions
house dust mite allergen extract food
Applies to: Odactra (house dust mite allergen extract)
ADJUST DOSING INTERVAL: Since sublingual preparations of allergenic extracts are meant to be absorbed directly from tissues under the tongue into the blood stream, consuming food or beverage during or immediately after administration may reduce the systemic bioavailability of the medication.
MONITOR: Coadministration of allergenic extracts for allergy immunotherapy with alcohol may potentiate the risk of allergic reactions, including anaphylaxis. According to some studies, alcohol is an augmenting factor influencing immunological mechanisms that can induce more severe allergic reactions and is involved in up to 15% of cases of anaphylactic reactions. Proposed mechanisms include an increase in allergen absorption from altered permeability of the intestinal epithelial barrier, enhancing mast cell and basophil activation, and an increase in serum IgE concentrations. A causal relationship with all allergenic extracts has not been established.
MANAGEMENT: Food or beverage should not be taken with, or for at least 5 minutes after, the administration of sublingual allergenic extracts. Patients should also avoid swallowing for about 1 minute following placement of the allergen extract under the tongue. Caution is advised if allergenic extracts for immunotherapy are used concomitantly with alcohol. Some manufacturers of peanut allergen extract recommend alcohol not be consumed for 2 hours before, or 2 hours after taking peanut allergen extract and if alcohol use cannot be avoided, that withholding or decreasing peanut allergen dosage should be considered. Individual prescribing information should be consulted for further guidance and clinical monitoring may be considered.
References (8)
- (2014) "Product Information. Grastek (timothy grass pollen allergen extract)." Merck & Co., Inc
- (2014) "Product Information. Ragwitek (ragweed pollen allergen extract)." Merck & Co., Inc
- (2014) "Product Information. Oralair (mixed grass pollens allergen extract)." Greer Laboratories Inc
- Cerner Multum, Inc. (2015) "Canadian Product Information."
- (2023) "Product Information. Palforzia (peanut allergen extract)." Aimmune Therapeutics
- (2022) "Product Information. Palforzia Level 1 (peanut allergen extract)." Aimmune Therapeutics UK Ltd
- Munoz-Cano R, Pascal M, Araujo G, et al. (2023) Mechanisms, Cofactors, and Augmenting Factors Involved in Anaphylaxis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623009/pdf/fimmu-08-01193.pdf
- (2023) "Product Information. Odactra (house dust mite allergen extract)." ALK-Abello Inc
famotidine food
Applies to: famotidine
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.